In March, Ford paid a record $425,000 fine for delays or omissions in providing information to the traffic safety agency about problems with ignition switches that could cause fires.
Many of the incidents described were a result of delays or omissions of care or treatment.
It was also proposed that patients with intellectual disabilities may be less likely to challenge errors or delays to their care or that they may fail to comply with investigations or treatment, consequently resulting in delays or omissions.
A compliant user was defined as a woman who always used her contraceptive method without no delays or omissions, according to the question in the self-administered questionnaire "Have you delayed/forgotten sometime in the use of your contraceptive method?
Identify which grade(s) of toxicity (and how many) trigger (i) treatment modification (defined as dose reductions, delays or drug omissions) and (ii) early discontinuation of treatment.
The purpose of this observational cohort study was to: Identify which grade(s) of toxicity (and how many) trigger (i) treatment modification (defined as dose reductions, delays or drug omissions) and (ii) early discontinuation of treatment.
It would seem important to further analyze the effect of IBR on other chemotherapy-related outcomes, such as dose reduction, delay during cycles, incomplete regimens or omission, as these also represent aspects of oncological safety.
Prospectively defined chemotherapy dose modifications (dose omission, delay or reduction) were based on the worst grades of haematological and non-haematological toxicity during chemoradiotherapy.
Nonetheless, 62 patients (55%) did not undergo the planned five cycles of cisplatin due to treatment toxicity (31%) or non-compliance because of delayed administration of the first cycle or omission of a cycle for reasons other than toxicity (21%).
Continued treatment at this dose-level beyond six to eight weeks may not be feasible because of delayed onset thrombocytopenia that would then persist, necessitating the deferral, reduction or omission of subsequent PR-104 dosing.
